AWM
ADPT icon

Affinity Wealth Management’s Adaptive Biotechnologies ADPT Stock Holding History

Affinity Wealth Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.35M Buy
342,569
+19,416
+6% +$297K 0.95% 24
2026
Q1 		$4.49M Buy
323,153
+8,802
+3% +$140K 0.68% 32
2025
Q4 		$5.11M Buy
314,351
+10,818
+4% +$177K 0.73% 30
2025
Q3 		$4.54M Buy
+303,533
New +$3.7M 0.66% 34

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Affinity Wealth Management's ADPT Position: Q2 2026 in Review

Affinity Wealth Management increased its Adaptive Biotechnologies (ADPT) stake by 6% in Q2 2026, buying an estimated $297K and bringing the position to 342,569 shares worth $7.35M. The position accounts for 0.95% of the portfolio, ranked #24.

Affinity Wealth Management first reported a position in ADPT in Q3 2025 and has held it in 4 quarters since. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Affinity Wealth Management held 342,569 shares of Adaptive Biotechnologies worth $7.35M as of Q2 2026.
  • Affinity Wealth Management bought 19,416 Adaptive Biotechnologies shares in Q2 2026, an estimated $297K.
  • Adaptive Biotechnologies made up 0.95% of Affinity Wealth Management's portfolio in Q2 2026, its #24 holding.
  • Affinity Wealth Management first reported a position in Adaptive Biotechnologies in Q3 2025 and has held it in 4 quarters since.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Affinity Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.